Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 8,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Childhood Asthma, Childhood Anxiety, Childhood Depression
Interventions: STRONGer Together; Behavioral
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 8 Years to 12 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cervical Cancer, Precancerous Condition
Interventions: survey administration; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 24 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 8
States / cities: Cleveland, Ohio

Conditions: Infertility
Interventions: Age; Other
Lead sponsor: Main Line Fertility Center; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,586 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 55
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 51 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 34
States / cities: Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more

Conditions: Visual Acuity
Interventions: Dailies Total 1® Multifocal Contact Lenses, Air Optix® Multifocal Contact Lenses Plus HydraGlyde®; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Roswell, Georgia • Granville, Ohio • Memphis, Tennessee

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more

Conditions: Chronic Kidney Disease Stage 3
Interventions: AION-301, Placebo; Biological · Drug
Lead sponsor: AION Healthspan, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 77
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more

Conditions: Smoking, Endothelial Dysfunction
Interventions: Charcoal hookah, E-coal hookah, Cigarette, Carbon Monoxide inhalation, Room Air inhalation, vitamin C, tadalafil; Other · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Abdominoplasty
Interventions: Genius, eC02, PicoPlus, LaseMD, LaseMD Flex; Device
Lead sponsor: CynosureLutronic; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Billerica, Massachusetts

Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: idarubicin, cytarabine, bevacizumab, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 59 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anosognosia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Murmur, Heart, Innocent Murmurs, Heart Murmurs, Pathologic Murmur
Interventions: Use of Eko CORE electronic stethoscope; Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Frailty
Interventions: Mesenchymal Stem Cells (MSCs); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 36
States / cities: Los Angeles, California • Oakland, California • Aurora, Colorado + 30 more

Conditions: Hypertension
Interventions: Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg); Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 6 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more

Conditions: Prediabetes, Overweight, Obesity
Interventions: Prevent; Behavioral
Lead sponsor: Omada Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • San Fernando, California • Monroe, Washington

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Reproductive Research Technologies, LP; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: Phoenix, Arizona • Philadelphia, Pennsylvania • Beaumont, Texas + 2 more

Conditions: Genetics Syndrome, Ehlers-Danlos Syndrome
Interventions: Genotyping; Diagnostic Test
Lead sponsor: Boston University; Other
Eligibility: Not listed
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epidermal Nevi
Interventions: sirolimus topical gel 0.2%; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Feeding, Breast Milk Expression, Stress
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: Female only
Enrollment: 27 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

STRONGer Together: A Small Group Intervention for Children With Asthma and Anxiety/Depression

Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults

Mitochondrial Activity of Cumulus Cells From the Cumulus-oocyte Complex and Oocyte Competence

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Comparison of Two Silicone Hydrogel Multifocal Contact Lenses

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function

Histologic Evaluation of Tissue Following Lutronic System Exposure

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting

Mesenchymal Stem Cells for Age-Related Frailty

A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

Evaluation of Prevent in Underserved Populations

Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring and Nonlaboring Patients by Practicing Clinicians

Genetics of Ehlers-Danlos Syndrome

A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.

Stress and Breast Milk Study In the Neonatal Intensive Care Unit